Sylvester Comprehensive Cancer Center

  • RPL-001-16 - Hernandez Aya, Leonel

  • Investigator:
    Leonel Hernandez Aya
    RCname Email

    		Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone +1 (786) 5828551

    IRB: 20180802

    		SDG: Breast Cancer
    Disease Site(s):

    Bladder,Breast-Female,Colon,Melanoma, skin,Other Skin
    Sponsor: REPLIMUNE

    Enrolling Sites:

    Sylvester
    Title:

    RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
    Eligibility Criteria - NCT03767348 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201540 - Kesmodel Susan

  • Investigator:
    Susan Kesmodel
    RCname Email

    		Coordinator:

    IRB: 20201540

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: SCCC

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    Prospective Evaluation of Targeted Axillary Dissection After Neoadjuvant Systemic Therapy in Patients with Breast Cancer with Advanced Nodal Disease at Diagnosis
    Eligibility Criteria - NCT04998682 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220314 - Krill Jackson Elisa

  • Investigator:
    Elisa Krill Jackson
    RCname Email

    		Coordinator:

    IRB: 20220314

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: Greenwich LifeSciences Inc

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adju
    Eligibility Criteria - NCT05232916 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221166 - Krill Jackson Elisa

  • Investigator:
    Elisa Krill Jackson
    RCname Email

    		Coordinator:

    IRB: 20221166

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: SCCC

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    Free-HER: Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
    Eligibility Criteria - NCT05959291 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231310 - NEGRET LAWRENCE

  • Investigator:
    LAWRENCE NEGRET
    RCname Email

    		Coordinator:

    IRB: 20231310

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: BRIACELL

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    Randomized, Open-Label Study Of The BRIA-IMT Regimen And Check Point Inhibitor Vs Physicians Choice In Advanced Metastatic Breast Cancer (BRIA-ABC)
    Eligibility Criteria - NCT06072612 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220744 - Perez Alejandra

  • Investigator:
    Alejandra Perez
    RCname Email

    		Coordinator:

    IRB: 20220744

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: ETCTN

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    Randomized phase 2 clinical trial of nab-paclitaxel + durvalumab (MEDI4736) + tremelimumab + neoantigen vaccine vs. nab-paclitaxel + durvalumab (MEDI4736) + tremelimumab in patients with metastatic triple negative breast cancer
    Eligibility Criteria - NCT03606967 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230330 - Perez Alejandra

  • Investigator:
    Alejandra Perez
    RCname Email

    		Coordinator:

    IRB: 20230330

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: ASTRA ZENECA

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    Title:

    A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer
    Eligibility Criteria - NCT05774951 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230730 - Perez Alejandra

  • Investigator:
    Alejandra Perez
    RCname Email

    		Coordinator:

    IRB: 20230730

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: SOLTI Breast Cancer Research Group

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A Phase III, multicenter, open-label study of ribociclib vs. palbociclib in patients with advanced hormone receptor-positive/HER2-negative/HER2- Enriched (HER2-E) breast cancer - HARMONIA trial
    Eligibility Criteria - NCT05207709 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230888 - Perez Alejandra

  • Investigator:
    Alejandra Perez
    RCname Email

    		Coordinator:

    IRB: 20230888

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: Gilead Sciences, Inc.

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Plantation
    Sylvester
    Title:

    A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
    Eligibility Criteria - NCT05633654 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231050 - Perez Alejandra

  • Investigator:
    Alejandra Perez
    RCname Email

    		Coordinator:

    IRB: 20231050

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: ASTRA ZENECA

    Enrolling Sites:

    ABLEH
    Aventura
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
    Eligibility Criteria - NCT05952557 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221120 - Rojas Kristin

  • Investigator:
    Kristin Rojas
    RCname Email

    		Coordinator:

    IRB: 20221120

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: SCCC

    Enrolling Sites:

    Plantation
    Sylvester
    Title:

    A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause
    Eligibility Criteria - NCT05812924 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210118 - Valdes Frances

  • Investigator:
    Frances Valdes
    RCname Email

    		Coordinator:

    IRB: 20210118

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: Alliance

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
    Eligibility Criteria - NCT04457596 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231043 - Valdes Frances

  • Investigator:
    Frances Valdes
    RCname Email

    		Coordinator:

    IRB: 20231043

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: NRG

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score
    Eligibility Criteria - NCT05879926 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231161 - Valdes Frances

  • Investigator:
    Frances Valdes
    RCname Email

    		Coordinator:

    IRB: 20231161

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: DualityBio

    Enrolling Sites:

    ABLEH
    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)
    Eligibility Criteria - NCT06018337 *This information has been extracted from " www.clinicaltrials.gov"